Navigation Links
Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
Date:3/19/2009

ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr. Bhaskar Chaudhuri to the position of President, Valeant Pharmaceuticals International, effective March 10, 2009. In this role, Dr. Chaudhuri will assume responsibility for overseeing the Dow Services business, corporate business development activities, the branded generics operations in Mexico and Poland, and will be a member of Valeant's Executive Management Team.

About Dr. Bhaskar Chaudhuri

Prior to joining Valeant upon the Company's acquisition of Dow Pharmaceutical Sciences, Inc. on December 31, 2008, Dr. Chaudhuri served for seven years as President and Chief Executive Officer and a Member of Dow's Board of Directors. Before joining Dow, Dr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories, where he oversaw the research and development activities for its Cardiovascular, Neurology and Dermatology businesses, as well as a segment of its manufacturing operations.

Prior to his positions at Bertek, Dr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri joined Mylan through the acquisition of Penederm Inc., where he was the Vice President of R&D from 1992 to 1998.

Dr. Chaudhuri has over 20 years experience in pharmaceutical management service, research and development. He holds a Doctorate in Physical Pharmacy, a Masters of Science in Industrial Pharmacy and a Bachelors of Science in Pharmacy.

As is the case with other members of Valeant's senior management, Dr. Chaudhuri's compensation package is directly linked to the performance of Valeant and is intended to provide a strong and direct link to the company's future.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the future of Valeant's business and performance. These statements are based upon the current expectations and beliefs of Valeant's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to Valeant's ability to successfully integrate its acquisitions and to realize the benefits of these acquisitions and management's ability to improve operations, as well as other risks and uncertainties discussed in the company's filings with the SEC. The company cautions the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. The company also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this press release. The company undertakes no responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... Elizabeth Murray has ... parrots to join her with one on her shoulder and one on her arm. ... parking lot because of years of mitral valve prolapse. , The valves of the ...
(Date:5/3/2016)... ... ... Excessive panting in the car or cowering when new guests arrive are ... only manifests itself as trembling or ‘tail between the legs,’ but a pet ... about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn pet health products ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... ... 2016 , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) ... or rare procedures in an environment that looks and feels real. , Located in ... inventors and “hackers” to develop and test new devices or software platforms and see ...
(Date:5/3/2016)... OH (PRWEB) , ... May 03, 2016 , ... Each ... a leading cause of death across the United States and account for one death ... and mental impairments or are permanently disabled. HCR ManorCare is launching a video series ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology: